Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH | P24723 | 4/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LATS1 | O95835 | 6/20 | 0.37 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.37 |
| ▸ | SOD1 | P00441 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379645 | 0.84 | PRKCH (0.37) | PRKCHPRKCQPRKCEPRKCDMAPT | |
| SCHEMBL28961794 | 0.82 | ALDH1A1 (0.55) | MAPTRAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24379630 | 0.82 | NLRP3 (0.55) | ALDH1A1HPGDFLT1KDRNLRP3 | |
| SCHEMBL24379633 | 0.79 | NLRP3 (0.40) | PRKCHPRKCQPRKCEPRKCDLATS1 | |
| SCHEMBL24379644 | 0.78 | PRKCH (0.37) | PRKCHPRKCQPRKCEPRKCDMAPT | |
| SCHEMBL24855505 | 0.76 | NLRP3 (0.39) | PRKCHPRKCQPRKCEPRKCDLATS1 | |
| SCHEMBL30913262 | 0.76 | LATS1 (0.38) | PRKCHPRKCQPRKCEPRKCDALDH1A1 | |
| SCHEMBL25857309 | 0.76 | FLT1 (0.43) | MAPTRAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30770615 | 0.74 | KDR (0.39) | PRKCHPRKCQPRKCEPRKCDRAB9A | |
| SCHEMBL27157422 | 0.74 | KDR (0.39) | PRKCHPRKCQPRKCEPRKCDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4320102-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12441728-B2 | Pyridazine compounds for inhibiting NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12410167-B2 | Pyridazine compounds for inhibiting NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250250270-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-12351578-B2 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12312350-B2 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12281112-B2 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4537900-A2 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240368160-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-117510495-A | Pyridazine compounds for inhibiting NLRP3 | 万特斯治疗美国公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117500792-A | Pyridazine compounds for inhibiting NLRP3 | 万特斯治疗美国公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| US-20220340567-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022216971-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340567-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-12410167-B2 | Pyridazine compounds for inhibiting NLRP3 | NLRP3, NLRP1, NOD1 | PRKCH 1745/4885PRKCQ 982/4885PRKCE 1326/4885 |
| US-20240368160-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-12312350-B2 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | NLRP3, NLRP1, PYCARD | PRKCH 3136/4885PRKCQ 1408/4885PRKCE 1055/4885 |
| US-12281112-B2 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-12441728-B2 | Pyridazine compounds for inhibiting NLRP3 | NLRP3, NLRP1, NOD1 | PRKCH 1745/4885PRKCQ 982/4885PRKCE 1326/4885 |
| US-20250250270-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
| US-12351578-B2 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | PRKCH 1152/4885PRKCQ 699/4885PRKCE 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.